Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$1.16
-3.3%
$1.22
$0.84
$2.03
$44.23M0.99118,426 shs13,256 shs
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$0.42
-0.9%
$0.51
$0.26
$3.28
$12.36M3.451.09 million shs271,097 shs
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
$10.50
$0.37
$12.58
$2.56B0.831.07 million shs93,330 shs
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$5.10
+0.6%
$6.13
$2.09
$8.17
$136.32M1.74213,763 shs128,576 shs
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$4.64
-2.3%
$6.51
$3.26
$13.51
$299.98M-0.63857,576 shs597,810 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
+7.21%+7.21%-0.83%+9.17%-25.63%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
-2.10%+8.92%-9.01%-35.36%-82.93%
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
0.00%0.00%0.00%0.00%0.00%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-1.36%-0.78%-20.78%-23.30%+69.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
+1.28%+4.63%-26.01%-10.55%-62.09%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
2.6485 of 5 stars
3.50.00.00.03.23.31.3
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
3.8598 of 5 stars
3.51.00.04.31.13.30.6
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
3.833 of 5 stars
3.42.00.04.12.03.30.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
3.00
Buy$7.00503.45% Upside
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/A
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
N/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
3.00
Buy$14.33181.05% Upside
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.75
Moderate Buy$14.94221.93% Upside

Current Analyst Ratings

Latest SYRS, BOLT, SESN, RDHL, and TERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$13.00
4/1/2024
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
3/27/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $18.00
3/22/2024
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
3/18/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$5.50
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
$7.88M5.61N/AN/A$2.97 per share0.39
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$6.53M1.89$1.30 per share0.32$0.11 per share3.78
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
$40M0.00N/A3.39$0.78 per share0.00
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
$9.94M13.71N/AN/A$0.79 per share6.46
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$1M299.98N/AN/A$4.13 per share1.12

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$69.20M-$1.83N/AN/AN/A-878.58%-51.18%-37.81%5/9/2024 (Estimated)
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
$23.92MN/A0.00N/AN/AN/AN/A6/10/2024 (Estimated)
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$164.57M-$5.76N/AN/AN/A-1,656.34%-227.91%-75.60%5/8/2024 (Estimated)
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)

Latest SYRS, BOLT, SESN, RDHL, and TERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
-$1.23-$1.19+$0.04-$0.20$2.40 million$0.39 million
3/21/2024Q4 2023
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
-$0.47-$0.47N/A-$0.47$1.97 million$2.09 million
3/14/2024Q4 2023
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.29N/A-$0.29N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
N/AN/AN/AN/AN/A
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/AN/AN/AN/AN/A
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
N/AN/AN/AN/AN/A
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
0.15
5.17
5.17
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
N/A
0.84
0.61
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
N/A
6.10
6.10
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
2.07
3.95
3.95
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
22.39
22.39

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
86.70%
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
7.20%
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
16.45%
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
91.47%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Bolt Biotherapeutics, Inc. stock logo
BOLT
Bolt Biotherapeutics
10038.13 million27.30 millionNot Optionable
RedHill Biopharma Ltd. stock logo
RDHL
RedHill Biopharma
11329.70 million27.68 millionNo Data
Sesen Bio, Inc. stock logo
SESN
Sesen Bio
35203.49 million196.98 millionOptionable
Syros Pharmaceuticals, Inc. stock logo
SYRS
Syros Pharmaceuticals
6826.73 million23.94 millionOptionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
6664.65 million53.40 millionNot Optionable

SYRS, BOLT, SESN, RDHL, and TERN Headlines

SourceHeadline
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by AnalystsTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of "Moderate Buy" by Analysts
americanbankingnews.com - April 25 at 1:22 AM
Terns Pharmaceuticals Inc Ordinary SharesTerns Pharmaceuticals Inc Ordinary Shares
morningstar.com - April 18 at 6:23 PM
Intra-Cellular depression data has investors feeling goodIntra-Cellular depression data has investors feeling good
thepharmaletter.com - April 17 at 3:21 PM
Kumquat Biosciences joins forces with Takeda on I-O developmentKumquat Biosciences joins forces with Takeda on I-O development
thepharmaletter.com - April 17 at 3:21 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
finanznachrichten.de - April 11 at 8:35 AM
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business OfficerTerns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
globenewswire.com - April 10 at 4:05 PM
Madrigal announces US launch of NASH/MASH drug RezdiffraMadrigal announces US launch of NASH/MASH drug Rezdiffra
msn.com - April 9 at 10:28 AM
Vivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 millionVivo Capital entities sell Terns Pharmaceuticals shares worth $2.8 million
investing.com - April 5 at 10:17 AM
Vivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockVivo Opportunity, Llc Sells 138,066 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock
insidertrades.com - April 5 at 5:24 AM
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Major Shareholder Vivo Opportunity, Llc Sells 181,117 Shares
insidertrades.com - April 4 at 6:15 AM
This small-cap stock is expected to take off - if its weight-loss pill trial succeedsThis small-cap stock is expected to take off - if its weight-loss pill trial succeeds
morningstar.com - March 30 at 7:03 PM
This small-cap stock is expected to take off — if its weight-loss pill trial succeedsThis small-cap stock is expected to take off — if its weight-loss pill trial succeeds
marketwatch.com - March 28 at 3:24 PM
UBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00UBS Group Lowers Terns Pharmaceuticals (NASDAQ:TERN) Price Target to $18.00
marketbeat.com - March 27 at 3:09 PM
Here’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime SoonHere’s Why Ozempic And Mounjaro Rivals Won’t Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
msn.com - March 27 at 9:31 AM
Wall Streets Favorite Biotech Stocks? 3 Names That Could Make You Filthy RichWall Street's Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
investorplace.com - March 25 at 3:00 PM
Optimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial StabilityOptimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stability
markets.businessinsider.com - March 21 at 6:49 AM
TERN Apr 2024 15.000 callTERN Apr 2024 15.000 call
finance.yahoo.com - March 16 at 1:45 PM
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
globenewswire.com - March 14 at 4:05 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
finanznachrichten.de - March 12 at 4:18 AM
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid LeukemiaTerns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
globenewswire.com - March 11 at 4:05 PM
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
globenewswire.com - March 7 at 4:05 PM
Terns Pharmaceuticals to Participate in Upcoming March Investor ConferencesTerns Pharmaceuticals to Participate in Upcoming March Investor Conferences
globenewswire.com - February 27 at 4:05 PM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
finanznachrichten.de - February 9 at 9:57 AM
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive OfficerTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
finanznachrichten.de - February 7 at 5:40 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Bolt Biotherapeutics logo

Bolt Biotherapeutics

NASDAQ:BOLT
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
RedHill Biopharma logo

RedHill Biopharma

NASDAQ:RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Sesen Bio logo

Sesen Bio

NASDAQ:SESN
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.
Syros Pharmaceuticals logo

Syros Pharmaceuticals

NASDAQ:SYRS
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Terns Pharmaceuticals logo

Terns Pharmaceuticals

NASDAQ:TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.